These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33332576)

  • 21. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab.
    Criado PR; Criado RFJ; Pincelli TP; Yoshimoto TA; Naufal GGA; Abdalla BMZ
    Int J Dermatol; 2020 Oct; 59(10):1294-1295. PubMed ID: 32808279
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
    Chen YD; Maurer M; Yu M; Tu P; Zhao ZT
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240
    [No Abstract]   [Full Text] [Related]  

  • 24. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study.
    Abduelmula A; Georgakopoulos JR; Mufti A; Devani AR; Gooderham MJ; Hong CH; Jain V; Lansang P; Vender R; Prajapati VH; Yeung J
    J Cutan Med Surg; 2022; 26(3):319-320. PubMed ID: 34587789
    [No Abstract]   [Full Text] [Related]  

  • 25. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab.
    Baldallo C; León Román JC; Serón D; Agraz I; Solans R; Ramos N; Soler MJ
    Nefrologia (Engl Ed); 2021; 41(3):354-356. PubMed ID: 32826086
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.
    Bostan E; Zaid F; Karaduman A; Dogan S; Gulseren D; Yalici-Armagan B; Akdogan N; Ersoy-Evans S; Elcin G
    J Cosmet Dermatol; 2021 Nov; 20(11):3369-3375. PubMed ID: 34599630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A; Ergun T; Gimenez-Arnau AM
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [No Abstract]   [Full Text] [Related]  

  • 28. Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response.
    Yu M; Terhorst-Molawi D; Altrichter S; Hawro T; Chen YD; Liu B; Song XT; Zhao ZT; Maurer M
    Clin Exp Allergy; 2021 May; 51(5):730-734. PubMed ID: 33522024
    [No Abstract]   [Full Text] [Related]  

  • 29. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU.
    Ertaş R; Hawro T; Altrichter S; Özyurt K; Erol K; Ketenci Ertaş Ş; Maurer M
    Allergy; 2020 Feb; 75(2):468-470. PubMed ID: 31469912
    [No Abstract]   [Full Text] [Related]  

  • 30. Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab.
    Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
    Clin Exp Allergy; 2021 Dec; 51(12):1648-1652. PubMed ID: 34519110
    [No Abstract]   [Full Text] [Related]  

  • 31. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
    Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
    Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
    [No Abstract]   [Full Text] [Related]  

  • 32. Atopic status and thyroid autoimmunity do not predict omalizumab response in severe chronic spontaneous urticaria patients.
    Asero S
    Eur Ann Allergy Clin Immunol; 2024 May; 56(3):141-143. PubMed ID: 36786337
    [No Abstract]   [Full Text] [Related]  

  • 33. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?
    Thiede RM; Fazel M; MacDonald KM; Abraham I
    Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375
    [No Abstract]   [Full Text] [Related]  

  • 34. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
    Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
    J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
    [No Abstract]   [Full Text] [Related]  

  • 35. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
    Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
    Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
    Maurer M; Kolkhir P; Moñino-Romero S; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience.
    Akdaş E; Adışen E; Öztaş MO; Aksakal AB; İlter N; Gülekon A
    An Bras Dermatol; 2023; 98(2):240-242. PubMed ID: 36567165
    [No Abstract]   [Full Text] [Related]  

  • 38. Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab".
    Abdelmaksoud A; Goldust M; Vestita M
    Int J Dermatol; 2020 Nov; 59(11):1417-1418. PubMed ID: 32989738
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.
    Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440
    [No Abstract]   [Full Text] [Related]  

  • 40. Baseline D-dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria.
    Asero R; Marzano AV; Ferrucci S; Genovese G; Cugno M
    Allergy; 2019 Dec; 74(12):2538. PubMed ID: 31165493
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.